Alkermes Unveils New Research on ALKS 2680 at SLEEP 2025 Conference Alkermes plc is set to present pivotal research on ALKS 2680 for narcolepsy treatment at SLEEP 2025 in Seattle, showcasing extensive data and findings.

Alkermes Unveils New Research on ALKS 2680 at SLEEP 2025 Conference #Ireland #Dublin #Narcolepsy #ALKS_2680 #Alkermes_plc

Alkermes plc's Promising First Quarter 2025 Financial Results Highlight Key Developments Alkermes plc reveals positive financial outcomes for Q1 2025, showcasing strong revenues, a solid product pipeline, and strategic advancements in drug development.

Alkermes plc's Promising First Quarter 2025 Financial Results Highlight Key Developments #Ireland #Dublin #Alkermes #ALKS_2680 #VIVITROL